Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1

Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1 Curr Oncol Rep (2017) 19:64 DOI 10.1007/s11912-017-0627-0 BREAST CANCER (B OVERMOYER, SECTION EDITOR) Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1 1,2,3 1,2,3 François Bertucci & Anthony Gonçalves Springer Science+Business Media, LLC 2017 Abstract Introduction Purpose of Review The purpose of the review is to summarize the data regarding PD-L1 expression in breast cancer and the Despite considerable progresses over the past three decades, results of first clinical trials with PD-1 or PD-L1 inhibitors in 15% of patients with breast cancer still develop metastases patients with metastatic breast cancer. and die. Improved understanding of mammary oncogenesis Recent Findings PD-L1 expression is heterogeneous across has led to major therapeutic advances with the approval of primary breast cancers, and is generally associated with the several drugs targeting cancer cells. Examples include hor- presence of tumor-infiltrating lymphocytes and the presence mone therapy targeting the estrogen receptor (ER) pathway of poor-prognosis features such as high grade, and aggressive and targeted therapies directed against oncogenic proteins molecular subtypes (triple-negative (TN), basal, HER2- (HER2, EGFR, VEGF, PI3K/AKT/mTOR pathway, enriched). Early phase clinical trials using PD-1 or PD-L1 CDK4/6). Many other drugs are under development. inhibitors alone or in combination have shown objective http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Oncology Reports Springer Journals

Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1

Loading next page...
 
/lp/springer_journal/immunotherapy-in-breast-cancer-the-emerging-role-of-pd-1-and-pd-l1-qk9hpLBwr9
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Oncology
ISSN
1523-3790
eISSN
1534-6269
D.O.I.
10.1007/s11912-017-0627-0
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial